3016 Dihydrotachysterol Dihydrotachysterol belongs to the vitamin d and derivatives, a subclass of steroids and steroid derivatives within the organic compounds. This exogenous compound has the formula C28H46O and an average molecular weight of 398.66 g/mol. At room temperature, it exists as a solid. It is utilized as a bone density conservation agent and is recorded as being found in vitamins, the preparation of wort, household cleaning and consumer products such as other smoking requisites and non electric simulated smoking devices, and electrical and electronic equipment including magnets, antennas, and amplifiers. It is released in polystyrene and polypropylene plastics, and the recorded route of exposure is oral. The compound targets the vitamin D3 receptor (VDR). Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing the synthesis of type I collagen. Furthermore, vitamin D, when bound to the vitamin D receptor, stimulates the expression of several proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into the blood. 67-96-9 5311071 C28H46O 398.354870 White powder. 126°C 1.25e-04 g/L Oral Once hydroxylated to 25-hydroxydihydrotachysterol, the modified drug binds to the vitamin D receptor. The bound form of the vitamin D receptor serves as a transcriptional regulator of bone matrix proteins, inducing the expression of osteocalcin and suppressing synthesis of type I collagen. Vitamin D (when bound to the vitamin D receptor)stimulates the expression of a number of proteins involved in transporting calcium from the lumen of the intestine, across the epithelial cells and into blood. This stimulates intestinal calcium absorption and increases renal phosphate excretion. These are functions that are normally carried out by the parathyroid hormone. No indication of carcinogenicity to humans (not listed by IARC). Used for the prevention and treatment of rickets or osteomalacia, and to manage hypocalcemia associated with hypoparathyroidism or pseudohypoparathyroidism. Also used for the treatment of vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis). Toxicity associated with dihydrotachysterol is similar to that seen with large doses of vitamin D. Treatment of overdosage consists of withdrawal of dihydrotachysterol, bed rest, liberal intake of fluids, a low-calcium diet, and administration of a laxative. Hypercalcemic crisis with dehydration, stupor, coma, and azotemia requires more vigorous treatment. The first step should be hydration of the patient. Intravenous saline may quickly and significantly increase urinary calcium excretion. A loop diurectic (furosemide or ethacrynic acid) may be given with the saline infusion to further increase renal calcium excretion. Other reported therapeutic measures include dialysis or the administration of citrates, sulfates, phosphates, corticosteroids, EDTA (ethylenediaminetetraacetic acids), and mithramycin via appropriate regimens. (L1712) 2009-07-21T20:28:17Z 2026-05-14T16:57:23Z Dihydrotachysterol C06957 4591 Dihydrotachysterol DB01070 true CC(C)[C@@H](C)\C=C\[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1/C[C@@H](O)CC[C@@H]1C C28H46O InChI=1S/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1 ILYCWAKSDCYMBB-OPCMSESCSA-N 398.6642 398.354866094 Exogenous Solid 7.5 HMDB15203 CHEMBL2106324 4470607 <p>von Werder, F.; U.S. Patent 2,228,491; January 14,1941; assigned to Winthrop Chemical<br /> Company, Inc.</p> CHEM002336 DTXSID5022938 NS00041323 (1S,3E,4S)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylcyclohexan-1-ol 20.23 129.11219999999997 51.75864346638369 5 1 1 18.296174547011585 -1.357053253137133 0 3 7.86 -6.50 1.25e-04 g/l Organic compounds Lipids and lipid-like molecules Steroids and steroid derivatives Vitamin D and derivatives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 776t3gAAAAAQAAAAAwAAAAAAAAAdAAAAHwAAAIABBgBgAAAAAQMGAGAAAAAD AQYAYAAAAAEDBiA0AAAAAQEEBgBgAAAAAQMGAGgAAAADAwEGAGgAAAADAwEG IDQAAAABAQQGAGAAAAABAwYgNAAAAAEBBAYAYAAAAAICBgBgAAAAAgIGIDQA AAABAQQGACgAAAADBAYAYAAAAAICBgBgAAAAAgIGAGAAAAACAgYgJAAAAAIE BgBgAAAAAQMGAGgAAAADAwEGAGgAAAADAwEGACgAAAADBAYAYAAAAAICBiA0 AAAAAQEECABgAAAAAQEGAGAAAAACAgYAYAAAAAICBiA0AAAAAgEEBgBgAAAA AQMLAAEAAQIAAQMAAwQAAwUEAwUGCgIDAgMHBgcEAwcIAAcJAAkKAAoLAAsM AAwNBAMNDgAODwAPEAAQEQAREgANEyoCAwIMFBMUJAMUFSoCAwITGxUWBAQW FwAXGAAXGQAZGgAaGwAbHAARCQAbFQARDABCAwAAAAUJCgsMEQYODxARDA0G FhcZGhsVFwQAAAAAAAAAFg== 2026-09-19T04:00:40Z